# 4D Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/4d-medicine

- Industry: Medical Devices & Equipment
- Headquarters: Birmingham, UK
- Website: www.4dbiomaterials.co.uk
- Total disclosed funding: $4.4M
- Latest round: Series A (Jul 25, 2024)
- Investors on record: 4

## About

4D Medicine Limited specializes in developing innovative bioabsorbable materials for medical applications, particularly in enhancing surgical outcomes and patient quality of life through advanced technologies.4D Medicine Limited, founded in 2018 in Birmingham, UK, focuses on the design and development of bioabsorbable medical devices. The company has successfully completed four deals, with its most recent funding round being a Series A in July 2024, raising GBP 3.4 mn, led by Hollyhigh International Capital. The CEO, Phil Smith, oversees the company's strategic direction.4D Medicine's principal product offering is the innovative 4Degra® polymer, a patented bioabsorbable material developed by Professor Andrew Dove after 15 years of research. This implantable medical polymer is engineered for the design and development of novel bioabsorbable medical devices that can be manufactured using advanced 3D printing techniques, allowing for high resolution and flexibility in dimensional scale. The end use cases that 4D Medicine aims to address include improving surgical outcomes and enhancing patient quality of life globally. The company targets a range of stakeholders, including hospitals, surgical centers, and healthcare providers, facilitating the adoption of its products in diverse geographical markets such as North America, Europe, and Asia, where there is a growing demand for innovative medical solutions in the USD 6 billion global marketplace.4D Medicine generates revenue primarily through partnerships with healthcare institutions and medical device manufacturers, focusing on B2B transactions. These collaborations may involve bulk procurement agreements for the supply of their flagship product, 4Degra®, and potentially other related bioabsorbable medical devices tailored to specific surgical needs. The transaction structure typically includes negotiated contracts that define pricing and delivery terms, ensuring a steady flow of products to clients. The emphasis on innovative solutions positions the company to attract significant investments and secure long-term relationships with medical organizations, thereby enhancing revenue stability and growth potential.In July 2024, 4D Medicine Limited raised GBP 3.4 mn in Series A funding led by Oshen Holdings, with participation from Boundary Capital, DSW Ventures, SFC Capital, and other investors. The company aims to utilize this funding to complete pre-clinical testing for its initial line of products and apply for FDA approval before entering the US market. Plans for future growth also include the introduction of additional products designed to meet specific surgical needs and expanding into new markets in North America and Asia by 2025.

## Funding rounds

- Series A, Jul 25, 2024, $4.4M — Boundary Capital, SFC Capital, Hollyhigh International Capital, DSW Ventures

## Investors

- Boundary Capital — Series A
- SFC Capital (https://capitalatlas.ai/funds/sfc-capital) — Series A
- Hollyhigh International Capital (https://capitalatlas.ai/funds/hollyhigh-international-capital) — Series A
- DSW Ventures (https://capitalatlas.ai/funds/dsw-ventures) — Series A